SCHEMBL7230392

SCHEMBL7230392

CN(C)Cc1cnc2ccccn12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.58
GGPS1 O95749 1/20 0.49
FDPS P14324 1/20 0.49
RAB9A P51151 2/20 0.47
ALDH1A1 P00352 1/20 0.47
MAPT P10636 1/20 0.47
MAPK1 P28482 1/20 0.47
GPR84 Q9NQS5 1/20 0.46
DYRK1A Q13627 1/20 0.46
NPSR1 Q6W5P4 2/20 0.45
DRD4 P21917 1/20 0.44
DRD3 P35462 1/20 0.44
KDM4E B2RXH2 2/20 0.43
NPC1 O15118 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
IRAK4 Q9NWZ3 2/20 0.43
FLT3 P36888 1/20 0.41
ADORA3 P0DMS8 1/20 0.40
PDK1 Q15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8360107 0.80 GGPS1 (0.53) POLBGGPS1FDPSRAB9AALDH1A1
SCHEMBL25293278 0.78 GGPS1 (0.45) POLBGGPS1FDPSRAB9AALDH1A1
SCHEMBL12801878 0.77 GGPS1 (0.50) GGPS1FDPSRAB9AALDH1A1MAPT
SCHEMBL14255059 0.77 POLB (0.51) POLBRAB9AALDH1A1MAPTDYRK1A
SCHEMBL18265799 0.77 GGPS1 (0.53) GGPS1FDPSRAB9AALDH1A1MAPT
SCHEMBL9797098 0.77 GGPS1 (0.56) GGPS1FDPSRAB9AALDH1A1GPR84
SCHEMBL25767061 0.77 GGPS1 (0.53) POLBGGPS1FDPSRAB9AALDH1A1
SCHEMBL5755912 0.77 GGPS1 (0.53) POLBGGPS1FDPSRAB9AALDH1A1
SCHEMBL2017760 0.77 GGPS1 (0.53) GGPS1FDPSRAB9AALDH1A1GPR84
SCHEMBL28036377 0.77 GGPS1 (0.53) GGPS1FDPSRAB9AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4710923-A2 INDOLE AHR INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2026-03-18 EP disclosed
EP-3612030-B1 INDOLE AHR INHIBITORS AND USES THEREOF IKENA ONCOLOGY INC (US) 2025-12-24 EP disclosed
US-20250122205-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2025-04-17 US disclosed
US-12077542-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2024-09-03 US disclosed
CN-112390823-B Synthesis method of minodronic acid 鲁南制药集团股份有限公司 2023-11-21 CN disclosed
CN-112390794-B Preparation method of minodronic acid key intermediate 鲁南制药集团股份有限公司 2023-05-26 CN disclosed
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2023-01-26 US disclosed
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2023-01-26 US disclosed
US-11358969-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-06-14 US disclosed
US-11358969-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-06-14 US disclosed
US-5760021-A TREATING OR PREVENTING METABOLIC BONE DISORDERS THE PROCTER & GAMBLE COMPANY (US) 1998-06-02 US disclosed
EP-0788362-A1 PHOSPONOCARBOXYLATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) 1997-08-13 EP disclosed
WO-1993024131-A1 PHOSPONOCARBOXYLATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) 1993-12-09 WO disclosed
EP-0203271-B1 ANTIBACTERIAL COMPOUNDS, THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 1993-05-26 EP disclosed
US-4864022-A 3-Condensed imidazolium-cephem compounds TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1989-09-05 US disclosed
US-4788185-A Cephalosporin compounds TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1988-11-29 US disclosed
EP-0203271-A2 Antibacterial compounds, their production and use Takeda Chemical Industries, Ltd. (JP) 1986-12-03 EP disclosed
EP-0160252-A2 Antibacterial compounds Takeda Chemical Industries, Ltd. (JP) 1985-11-06 EP disclosed
EP-0033094-B1 IMIDAZO(1,2-A)PYRIDINES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SCHERING CORPORATION (US) 1984-10-10 EP disclosed
US-4450164-A ANTIULCER AND ANTISECRETORY AGENTS SCHERING CORPORATION (US) 1984-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11358969-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 POLB 4041/4885GGPS1 2983/4885FDPS 2150/4885
US-20250122205-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 POLB 4041/4885GGPS1 2983/4885FDPS 2150/4885
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 POLB 4041/4885GGPS1 2983/4885FDPS 2150/4885
US-12077542-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 POLB 4041/4885GGPS1 2983/4885FDPS 2150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.